On this page
What each program costs in Oregon
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Getting a GLP-1 online in Oregon
The Oregon Board of Pharmacy's February 2025 semaglutide position statement says pharmacies may not compound essentially copies of a commercially available drug, and that a lower price or added ingredients do not make a compounded GLP-1 something other than a copy.
Oregon Board of Pharmacy
The Board restates the federal ban on compounding copies of commercially available drugs.
“The federal Food Drug & Cosmetic Act (FD&C Act) prohibits pharmacies from compounding “drug products that are essentially copies of a commercially available drug product.””
https://www.oregon.gov/pharmacy/Documents/OBOP_Semalgutide_Position_Statement_v.2-2025.pdf · read Oct 29, 2026
Oregon Board of Pharmacy
A lower price is not a reason that qualifies.
“Other factors, such as a lower price, are not sufficient to establish that the compounded drug product is not essentially a copy of the commercially available drug product.”
https://www.oregon.gov/pharmacy/Documents/OBOP_Semalgutide_Position_Statement_v.2-2025.pdf · read Oct 29, 2026
Oregon Board of Pharmacy
Adding other substances does not qualify either.
“Adding additional substances to a compounded product that is otherwise an essential copy of a commercially available drug product is not included in FDA’s list of circumstances meeting Section 503A(b)(2)’s requirements.”
https://www.oregon.gov/pharmacy/Documents/OBOP_Semalgutide_Position_Statement_v.2-2025.pdf · read Oct 29, 2026
Does Oregon Medicaid (Oregon Health Plan) cover GLP-1s for weight loss?
Not covered for weight loss
Oregon's fee-for-service criteria say drugs prescribed only for weight management are not currently covered and that adults are denied when these drugs are indicated for weight loss, so it does not cover Wegovy or Zepbound for weight loss alone in adults. Read from state documents Nov 6, 2026.
What Oregon Medicaid (Oregon Health Plan)'s documents say about each drug for weight loss. Read Nov 6, 2026. Oregon Health Authority, with the Oregon State University Drug Use Research and Management program.
WegovyNo
For adults, prior authorization for established cardiovascular disease or MASH with fibrosis. Members in the EPSDT program get case-by-case review.
“Drugs prescribed for only weight management (overweight or obesity) are NOT currently covered”
Oregon Health Authority fee-for-service PA criteria, published at orpdl.org · Effective Mar 1, 2026 · read Nov 6, 2026
“Semaglutide is not currently covered for adults who do not have established cardiovascular disease, metabolic dysfunction-associated steatohepatitis (MASH), or type 2 diabetes.”
Oregon Health Authority fee-for-service PA criteria, published at orpdl.org · Effective Mar 1, 2026 · read Nov 6, 2026
ZepboundNo
For adults, prior authorization for moderate to severe sleep apnea with BMI of 30 or more.
“Tirzepatide is not currently covered for adults who do not have established obstructive sleep apnea or type 2 diabetes.”
Oregon Health Authority fee-for-service PA criteria, published at orpdl.org · Effective Mar 1, 2026 · read Nov 6, 2026
“drugs are not covered by OHP for adults when indicated for weight loss.”
Oregon Health Authority fee-for-service PA criteria, published at orpdl.org · Effective Mar 1, 2026 · read Nov 6, 2026
OzempicNo
Handled under separate GLP-1 criteria for type 2 diabetes. Semaglutide is not covered for adults without cardiovascular disease, MASH or type 2 diabetes.
“PA Criteria for approval of semaglutide (OZEMPIC and RYBELSUS) and tirzepatide (MOUNJARO) for type 2 diabetes.”
Oregon Health Authority fee-for-service PA criteria, published at orpdl.org · Effective Mar 1, 2026 · read Nov 6, 2026
“Semaglutide is not currently covered for adults who do not have established cardiovascular disease, metabolic dysfunction-associated steatohepatitis (MASH), or type 2 diabetes.”
Oregon Health Authority fee-for-service PA criteria, published at orpdl.org · Effective Mar 1, 2026 · read Nov 6, 2026
MounjaroNo
Handled under separate GLP-1 criteria for type 2 diabetes. Tirzepatide is not covered for adults without sleep apnea or type 2 diabetes.
“PA Criteria for approval of semaglutide (OZEMPIC and RYBELSUS) and tirzepatide (MOUNJARO) for type 2 diabetes.”
Oregon Health Authority fee-for-service PA criteria, published at orpdl.org · Effective Mar 1, 2026 · read Nov 6, 2026
“Tirzepatide is not currently covered for adults who do not have established obstructive sleep apnea or type 2 diabetes.”
Oregon Health Authority fee-for-service PA criteria, published at orpdl.org · Effective Mar 1, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Oregon Health Authority, with the Oregon State University Drug Use Research and Management program documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
4,607 prescriptions
Ozempic and Mounjaro, 2025
33,709 prescriptions
Neighbours covering weight loss
0 of 4
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Oregon Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Oregon Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Oregon Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Oregon Medicaid pay for?
72,779 GLP-1 prescriptions in 2025, 28th of the 50 states and DC, with $65.9 million reimbursed before rebates. Counting the share other payers covered, $67.3 million.
Prescriptions, 2025
72,779
28th of 51
Medicaid paid
$65.9M
31st of 51, before rebates
Per prescription
$906
$1,051 nationally
Weight-loss brands
6.3%
20th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Oregon is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 6.3% of Oregon Medicaid's GLP-1 prescriptions in 2025 (4,607). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Ozempic was Oregon Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Ozempic | 28,285 | 39% | $26.9 million | $950 |
| Trulicity | 24,426 | 34% | $23.7 million | $971 |
| Liraglutide (generic) | 8,933 | 12% | $3.8 million | $421 |
| Mounjaro | 5,424 | 7.5% | $5.3 million | $974 |
| Zepboundapproved for weight management | 3,147 | 4.3% | $3.2 million | $1,024 |
| Wegovyapproved for weight management | 1,460 | 2.0% | $1.8 million | $1,265 |
| Rybelsus | 822 | 1.1% | $1.0 million | $1,218 |
| Bydureon | 269 | 0.4% | $216,438 | $805 |
| Victoza | 13 | 0.0% | $7,272 | $559 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Oregon?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Oregon and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 4 states next to Oregon covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than Oregon's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Oregon | Not covered | 19 | $39/mo |
| California | Not covered | 17 | $39/moWellmedr |
| Idaho | Not covered | 19 | $39/moWellmedr |
| Nevada | Not covered | 19 | $39/moWellmedr |
| Washington | Not covered | 18 | $39/moWellmedr |






















